AVITA Medical Secures $25.5M US Government Contract for Burn Emergency Stockpile
AVITA Medical secures decade-long US government contract for burn emergency preparedness
AVITA Medical (ASX: AVH) has entered into a 10-year agreement valued at up to $25.5 million to strengthen US national preparedness for burn mass casualty incidents. The contract, awarded under Project BioShield, includes approximately $3.97 million in access-maintenance fees and readiness support whilst providing procurement options for an additional amount over the contract term.
The agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services, requires AVITA Medical to maintain an inventory of RECELL products available for immediate deployment. This builds on a decade-long partnership between the company and BARDA to advance burn care innovation and strengthen public health readiness.
Under the contract, AVITA Medical will provide logistics, quality assurance, and deployment readiness to meet BARDA’s mission for preparedness. In the event of a burn mass casualty incident, the RECELL products will be deployed to designated centres with trained staff to ensure rapid and effective use.
When big ASX news breaks, our subscribers know first
Understanding BARDA partnerships and why they matter for medical device companies
BARDA operates within the Administration for Strategic Preparedness and Response and functions as the US government’s primary mechanism for developing and procuring medical countermeasures. Project BioShield specifically authorises the government to stockpile critical medical products for deployment during national emergencies.
Government contracts of this type typically distinguish between guaranteed revenue streams and conditional procurement options. The guaranteed fees provide baseline recurring income, whilst procurement options create upside potential should emergency deployment become necessary.
Burn mass casualty incident preparedness requires specialised inventory arrangements because these events, whilst rare, demand immediate access to large quantities of advanced wound care products. BARDA partnerships position companies within essential government supply chains, creating competitive positioning advantages and long-term revenue pathways that extend beyond commercial market dynamics.
For medical device companies, BARDA agreements signal regulatory confidence and provide validation of clinical efficacy at the institutional level. These partnerships often support broader commercial adoption as healthcare providers observe government endorsement of specific technologies.
Breaking down the contract economics
The $25.5 million total contract value comprises distinct revenue components with different risk profiles. Approximately $3.97 million represents expected revenue paid over 10 years in the form of annual access-maintenance fees and readiness support. The balance reflects procurement options that BARDA may exercise over the contract term.
| Contract Component | Value | Timing | Revenue Type |
|---|---|---|---|
| Total contract value | Up to $25.5M | 10 years | Maximum potential |
| Expected fees | ~$3.97M | Paid over 10 years | Recurring/expected |
| Procurement options | Balance of total | At BARDA’s discretion | Conditional |
| Unit availability | 3,000 units | Available any time | Inventory obligation |
AVITA Medical must maintain an inventory of RECELL products available for immediate deployment upon notice from BARDA. The company has agreed to discounted pricing as part of the government value proposition, whilst also supporting surge procurement of additional product to ensure scalable emergency response capacity.
The contract structure provides predictable baseline cash flow whilst creating upside potential if mass casualty incidents require product deployment. The 10-year term extends revenue visibility significantly beyond typical commercial sales cycles.
AVITA Medical’s RECELL technology and strategic positioning
RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin, offering an innovative solution for improved clinical outcomes at the point-of-care. The system has received FDA approval for the treatment of thermal burns and trauma wounds, positioning it as an advanced point-of-care solution for acute wound management.
Cary Vance, Interim Chief Executive Officer
“Through this agreement, AVITA is supporting national preparedness by helping expand access to RECELL during mass casualty incidents. We value our ongoing collaboration with BARDA to strengthen the nation’s ability to respond when it matters most.”
The company’s broader product portfolio includes:
- RECELL: FDA-approved for thermal burns and trauma wounds
- Cohealyx: AVITA Medical-branded collagen-based dermal matrix (exclusive US rights to market, sell, and distribute)
- PermeaDerm: Biosynthetic wound matrix (exclusive US manufacturing and distribution rights)
- RECELL GO: Available in international markets
RECELL’s international regulatory footprint extends across multiple jurisdictions:
- CE mark approval (Europe)
- TGA registration (Australia)
- PMDA approval (Japan)
- FDA approval (United States)
The BARDA contract reinforces RECELL’s position within the acute wound care market by validating the technology’s role in emergency preparedness infrastructure. Government adoption often supports broader commercial credibility as healthcare providers observe institutional endorsement of specific treatment modalities.
The next major ASX story will hit our subscribers first
What this means for shareholders
The BARDA agreement provides AVITA Medical shareholders with revenue stability through expected fees whilst creating conditional upside potential through procurement options. The 10-year contract term extends revenue visibility substantially beyond typical commercial product sales cycles.
Key investment implications include:
- Expected recurring revenue of approximately $3.97 million over 10 years provides baseline cash flow independent of commercial market performance
- Potential upside of up to $25.5 million if BARDA exercises procurement options during the contract term
- Government endorsement supporting commercial positioning and competitive differentiation within the acute wound care market
- Long-term contract providing extended revenue visibility and strategic partnership validation
The agreement continues an established decade-long relationship with BARDA rather than representing a new partnership. This sustained collaboration demonstrates ongoing government confidence in AVITA Medical’s manufacturing capabilities, logistics infrastructure, and product efficacy.
For investors, the contract structure balances expected income with conditional upside whilst positioning AVITA Medical within critical national emergency preparedness infrastructure. The $3.97 million expected component provides predictable revenue, whilst the procurement options create scenarios for material contract value realisation should burn mass casualty incidents occur.
Don’t Miss the Next Healthcare Breakthrough
Join 20,000+ investors getting FREE breaking ASX news delivered to your inbox within minutes, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment market-moving announcements hit the ASX across healthcare, technology, finance, and beyond.